Palavras-chave
Tratamiento, odontología oncológica
Como Citar
Tratamiento odontológico integral del paciente oncológico. Parte II. (2019). Odontoestomatología, 15(22), 46-63. https://odon.edu.uy/ojs/index.php/ode/article/view/116
Resumo
El tratamiento odontológico del paciente con cáncer es uno de los mayores desafíos a los que se puede enfrentar el odontólogo, ya que requiere de una atención meticulosa, coordinada y con la participación de un equipo multidisciplinario, cuyo objetivo debe ser asistir al paciente de manera integral y con la menor cantidad posible de efectos secundarios. Para lograr este objetivo se debe seguir un protocolo odontológico dividido en tres etapas: pre, intra y post terapia oncológica, que abarcan diversos tratamientos. El paciente acude al hospital para realizar el tratamiento oncológico específco y este debe ofrecerle la asistencia intra y post cirugía en condiciones hospitalarias o sanatoriales. Este artículo está dirigido al odontólogo general integrado al equipo de salud y continúa la descripción, iniciada en la parte I, de las patologías, agudas y crónicas, generadas por la terapia oncológica, como prevenirlas y como tratarlas
Referências
1. Lanza Echeveste, D. G.: Tratamiento odontológico integral del paciente oncológico. Parte 1. Odontoestomatología. Mayo 2011; XIII, (17): 14-25.
2. Gay Escoda C & Berini Aytés L. Cirugía bucal. 1ª Edición. España. Ediciones Ergon S.A. 1999. Capítulo 24.
3. Garfunkel AA. Oral mucositis. Te62 Dr. Lanza Echeveste, Damián Guillermo search for a solution. N. Eng. J. Med. 2004. 351 (25), 2649-2651.
4. Kumar V, Abbas AK, Fausto N. Robbins & Cotran Patología estructural y funcional. 7ªed. Elsevier España. 2005.
5. Mealey BL, Semba SE. & Hallmon WW. Dentistry and the cancer patient: Part 1-Oral manifestations and complications of chemotherapy. Compend. 1994, 15
(10): 1252-1261.
6. Pasqualotto AC, Rosa DD, Medeiros LR et al. Candidaemia and cancer: patients are not all the same. BMC Infect Dis; 2006, 6: 50.
7. Akintoye SO, Brennan MT, Graber CJ et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicaemia in hematopoietic stem
cell and bone marrow transplant recipients. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 94 (5): 581-588.
8. Pumarola A, Rodríguez-Torres A, GarcíaRodríguez JA et al. Microbiología y parasitología médica. 2ª Edición. España. Masson, S.A. 1998.
9. De Vita Jr VT, Hellman S, Rosenberg SA. Cancer. Principles & practice of oncology. 5ed. Philadelphia: LippincottRaven, 1997.
10. Bensadoun RJ, Patton LL, Lalla RV et al. Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Support Care Cancer.
2011, 19(6): 737-44.
11. Garg A & Guez G. Head and neck cancer, dental implants, and dental oncology. Dent. Update. 2011, 22(1): 1-8.
12. Yang C, Gong W, Lu J et al. Antifungal drug susceptibility of oral Candida albicans isolates may be associated with apoptotic responses to Amphotericin B. J. Oral Pathol. & Med.; 2010, 39(2): 182-7.
13. Langdon JD & Henk JM. Malignant tumours of the mouth, jaws et salivary glands. 2nd Edition. England. Edward Arnold Editors. 1995.
14. Regezi JA, Sciubba JJ. Patología bucal. Correlaciones clinicopatológicas. 3ª Edición. México. Mc Graw-Hill Interamericana. 2006.
15. Barclay SC, Turani D. Current practice in dental oncology in the U.K. Dent. Update. 2010, 37(8): 555-561.
16. Corvo R, Amichetti M, Ascarelli A. et al: Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and
neck tumour: results from a double-blind placebo-controlled trial. Eur. J. Cancer Care. 2008, 17(3): 270-7.
17. Parikh PM & Davison SP. Herpes zoster after reconstruction for head and neck cancer. Plast. Reconstr. Surg. 2008, 122(6): 211e-213e.
18. Epstein JB, Gorsky M, Hancock P, et al.: Te prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 94 (6): 712-716.
19. Lugliè PF, Mura G, Mura A, et al.: Prevenzione delle paradontopatie e delle stomatomucositi in corso di chemoterapia antineoplastica. Studio clinico. Minerva
Stomatol. 2002, 51 (6): 231-239.
20. Goodman & Gilman: Las bases farmacológicas de la terapéutica. 10ed. México: Mc Graw-Hill Interamericana. 2003. Volumen II, Sección IX. Capítulo 52, p
1371-1387.
21. Abdelsayed RA, Sumner T, Allen CM. et al. Oral precancerous and malignant lesions associated with graft-versus-host disease: Report of 2 cases. Oral Surg,
Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 93 (1): 75-80.Tratamiento odontológico integral del paciente oncológico. Parte II 63
22. Bonan PR, Lopes MA, Pires FR. et al. Dental management of low socioeconomic level patients before radiotherapy of the head and neck with special emphasis on the prevention of osteorradionecrosis. Braz. Dent. J. 2006, 17(4): 336-42.
23. Cankar K, Finderle Z, Jan J. Te effect of hyperbaric oxygenation on postradiation xerostomia and saliva in patients with head and neck tumours. Caries Res. 2011, 45(2): 136-41.
24. Sennhenn-Kirchner S, Freund F, Grundmann S et al. Dental therapy before and after radiotherapy--an evaluation on patients with head and neck malignancies.
Clin. Oral Investig. 2009, 13(2): 157-64.
25. Flowers M.E, Inamoto Y, Carpenter PA.et al: Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011, 117(11): 3214-9.
26. Madrid C, Bouferrache K, Abarca M. et al. Bisphosponate-related osteonecrosis of the jaws: How to manage cancer patients. Oral Oncol. 2010, 46(6): 468-470.
27. Madrid C, Bouferrache K, Abarca, M. et al.: Osteoradionecrosis: an update. Oral Oncol. 2010, 46(6): 471-474.
28. Sabater Recolons MM, Rodríguez de Rivera Campillo ME, López López J & Chimenos Küstner E. Manifestaciones orales secundarias al tratamiento oncológico.
Pautas de actuación odontológica. Av. Odontoestomatol. 2006, 22(6): 335-342.
29. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of
the Jaws—2009 Update. J. Oral Maxillofac. Surg. 2009 Suppl. 1, 67:2-12.
30. Pautke C, Bauer F, Tischer T et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2009,
67:471-476.
31. Pautke C, Bauer F, Bissinger O et al. Tetracycline bone fluorescence: A valuable marker for osteonecrosis characterization and therapy. J. Oral Maxillofac. Surg.
2010, 68:125-129.
2. Gay Escoda C & Berini Aytés L. Cirugía bucal. 1ª Edición. España. Ediciones Ergon S.A. 1999. Capítulo 24.
3. Garfunkel AA. Oral mucositis. Te62 Dr. Lanza Echeveste, Damián Guillermo search for a solution. N. Eng. J. Med. 2004. 351 (25), 2649-2651.
4. Kumar V, Abbas AK, Fausto N. Robbins & Cotran Patología estructural y funcional. 7ªed. Elsevier España. 2005.
5. Mealey BL, Semba SE. & Hallmon WW. Dentistry and the cancer patient: Part 1-Oral manifestations and complications of chemotherapy. Compend. 1994, 15
(10): 1252-1261.
6. Pasqualotto AC, Rosa DD, Medeiros LR et al. Candidaemia and cancer: patients are not all the same. BMC Infect Dis; 2006, 6: 50.
7. Akintoye SO, Brennan MT, Graber CJ et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicaemia in hematopoietic stem
cell and bone marrow transplant recipients. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 94 (5): 581-588.
8. Pumarola A, Rodríguez-Torres A, GarcíaRodríguez JA et al. Microbiología y parasitología médica. 2ª Edición. España. Masson, S.A. 1998.
9. De Vita Jr VT, Hellman S, Rosenberg SA. Cancer. Principles & practice of oncology. 5ed. Philadelphia: LippincottRaven, 1997.
10. Bensadoun RJ, Patton LL, Lalla RV et al. Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Support Care Cancer.
2011, 19(6): 737-44.
11. Garg A & Guez G. Head and neck cancer, dental implants, and dental oncology. Dent. Update. 2011, 22(1): 1-8.
12. Yang C, Gong W, Lu J et al. Antifungal drug susceptibility of oral Candida albicans isolates may be associated with apoptotic responses to Amphotericin B. J. Oral Pathol. & Med.; 2010, 39(2): 182-7.
13. Langdon JD & Henk JM. Malignant tumours of the mouth, jaws et salivary glands. 2nd Edition. England. Edward Arnold Editors. 1995.
14. Regezi JA, Sciubba JJ. Patología bucal. Correlaciones clinicopatológicas. 3ª Edición. México. Mc Graw-Hill Interamericana. 2006.
15. Barclay SC, Turani D. Current practice in dental oncology in the U.K. Dent. Update. 2010, 37(8): 555-561.
16. Corvo R, Amichetti M, Ascarelli A. et al: Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and
neck tumour: results from a double-blind placebo-controlled trial. Eur. J. Cancer Care. 2008, 17(3): 270-7.
17. Parikh PM & Davison SP. Herpes zoster after reconstruction for head and neck cancer. Plast. Reconstr. Surg. 2008, 122(6): 211e-213e.
18. Epstein JB, Gorsky M, Hancock P, et al.: Te prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 94 (6): 712-716.
19. Lugliè PF, Mura G, Mura A, et al.: Prevenzione delle paradontopatie e delle stomatomucositi in corso di chemoterapia antineoplastica. Studio clinico. Minerva
Stomatol. 2002, 51 (6): 231-239.
20. Goodman & Gilman: Las bases farmacológicas de la terapéutica. 10ed. México: Mc Graw-Hill Interamericana. 2003. Volumen II, Sección IX. Capítulo 52, p
1371-1387.
21. Abdelsayed RA, Sumner T, Allen CM. et al. Oral precancerous and malignant lesions associated with graft-versus-host disease: Report of 2 cases. Oral Surg,
Oral Med, Oral Pathol, Oral Radiol, Endod. 2002, 93 (1): 75-80.Tratamiento odontológico integral del paciente oncológico. Parte II 63
22. Bonan PR, Lopes MA, Pires FR. et al. Dental management of low socioeconomic level patients before radiotherapy of the head and neck with special emphasis on the prevention of osteorradionecrosis. Braz. Dent. J. 2006, 17(4): 336-42.
23. Cankar K, Finderle Z, Jan J. Te effect of hyperbaric oxygenation on postradiation xerostomia and saliva in patients with head and neck tumours. Caries Res. 2011, 45(2): 136-41.
24. Sennhenn-Kirchner S, Freund F, Grundmann S et al. Dental therapy before and after radiotherapy--an evaluation on patients with head and neck malignancies.
Clin. Oral Investig. 2009, 13(2): 157-64.
25. Flowers M.E, Inamoto Y, Carpenter PA.et al: Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011, 117(11): 3214-9.
26. Madrid C, Bouferrache K, Abarca M. et al. Bisphosponate-related osteonecrosis of the jaws: How to manage cancer patients. Oral Oncol. 2010, 46(6): 468-470.
27. Madrid C, Bouferrache K, Abarca, M. et al.: Osteoradionecrosis: an update. Oral Oncol. 2010, 46(6): 471-474.
28. Sabater Recolons MM, Rodríguez de Rivera Campillo ME, López López J & Chimenos Küstner E. Manifestaciones orales secundarias al tratamiento oncológico.
Pautas de actuación odontológica. Av. Odontoestomatol. 2006, 22(6): 335-342.
29. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of
the Jaws—2009 Update. J. Oral Maxillofac. Surg. 2009 Suppl. 1, 67:2-12.
30. Pautke C, Bauer F, Tischer T et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2009,
67:471-476.
31. Pautke C, Bauer F, Bissinger O et al. Tetracycline bone fluorescence: A valuable marker for osteonecrosis characterization and therapy. J. Oral Maxillofac. Surg.
2010, 68:125-129.